Shoma Yamamoto
Overview
Explore the profile of Shoma Yamamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
9
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto S, Yamasaki T, Matsue T, Yukimatsu N, Otoshi T, Kato M, et al.
Hinyokika Kiyo
. 2025 Feb;
71(1):5-8.
PMID: 39901343
A 79-year-old woman underwent radical cystectomy after neoadjuvant chemotherapy for urothelial carcinoma of bladder (high grade, pT3aN0M0). Six months later, a computed tomography scan revealed multiple lung metastases. Salvage treatment...
2.
Kato M, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1937-1945.
PMID: 39379757
Background: Radical cystectomy in women generally includes the removal of the uterus, ovaries, and anterior vaginal wall, but the criteria for reproductive organ sparing are not clear. Methods: A total...
3.
Fujita K, Kato M, Kosugi Y, Sekido Y, Matsui N, Masuda K, et al.
Hinyokika Kiyo
. 2024 Jul;
70(6):173-177.
PMID: 38967030
A 74-year-old man visited the urology clinic with the chief complaint of urinary retention in December 2014. Serum level of initial prostate specific antigen (PSA) was 50 ng/ml and he...
4.
Matsue T, Kato M, Kosugi Y, Ishizaki K, Masuda H, Yamamoto S, et al.
Jpn J Clin Oncol
. 2023 Nov;
54(2):182-191.
PMID: 37967156
Objective: Adjuvant nivolumab prolonged disease-free survival compared with placebo in patients at high risk of recurrence following radical cystectomy or radical nephroureterectomy in the CheckMate 274 trial. However, the ideal...
5.
Yamamoto S, Kato M, Matsue T, Yukimatsu N, Takeyama Y, Otoshi T, et al.
Jpn J Clin Oncol
. 2023 Oct;
54(2):221-224.
PMID: 37886853
New approaches involving immune checkpoint inhibitors and antibody-drug conjugates prolong overall survival in patients with metastatic urothelial carcinoma. However, the access to such systemic therapy in clinical practice is suboptimal,...
6.
Yamamoto S, Kato M, Takeyama Y, Azuma Y, Yukimatsu N, Hirayama Y, et al.
Br J Cancer
. 2023 Apr;
128(12):2197-2205.
PMID: 37069346
Background: Radiotherapy (RT) has recently been highlighted as a partner of immune checkpoint inhibitors. The advantages of RT include activation of lymphocytes while it potentially recruits immunosuppressive cells, such as...
7.
Yamamoto S, Kato M, Takeyama Y, Yukimatsu N, Hirayama Y, Otoshi T, et al.
Urol Oncol
. 2021 Dec;
40(5):194.e7-194.e14.
PMID: 34852939
Background: Recently, switch maintenance with avelumab has been approved for the treatment of advanced or metastatic urothelial carcinoma (UC), with no progression after four to six cycles of first-line platinum-based...